Aurinia Pharmaceuticals Inc. (AUPH) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 311.51M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $311.51M | (m) | (m) |
| 2026-03-31 | (m) | $298.30M | (m) | (m) |
| 2025-12-31 | (m) | $283.06M | (m) | (m) |
| 2025-09-30 | (m) | $265.81M | (m) | (m) |
| 2025-06-30 | (m) | $260.11M | (m) | (m) |
| 2025-03-31 | (m) | $247.29M | (m) | (m) |
| 2024-12-31 | (m) | $235.13M | (m) | (m) |
| 2024-09-30 | (m) | $220.36M | (m) | (m) |
| 2024-06-30 | (m) | $207.10M | (m) | (m) |
| 2024-03-31 | (m) | $191.41M | (m) | (m) |
| 2023-12-31 | (m) | $175.51M | (m) | (m) |
| 2023-09-30 | (m) | $158.85M | (m) | (m) |
| 2023-06-30 | (m) | $160.12M | (m) | (m) |
| 2023-03-31 | (m) | $146.81M | (m) | (m) |
| 2022-12-31 | (m) | $134.03M | (m) | (m) |
| 2022-09-30 | (m) | $129.00M | (m) | (m) |
| 2022-06-30 | (m) | $87.89M | (m) | (m) |
| 2022-03-31 | (m) | $66.32M | (m) | (m) |
| 2021-12-31 | (m) | $45.60M | (m) | (m) |
| 2021-09-30 | (m) | $72.23M | (m) | (m) |
| 2021-06-30 | (m) | $57.59M | (m) | (m) |
| 2021-03-31 | (m) | $51.00M | (m) | (m) |
| 2020-12-31 | (m) | $50.12M | (m) | (m) |
| 2020-09-30 | (m) | $117.00K | (m) | (m) |
| 2020-06-30 | (m) | $318.00K | (m) | (m) |
| 2020-03-31 | (m) | $318.00K | (m) | (m) |
| 2019-12-31 | (m) | $318.00K | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $463.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |